top of page
Search

3R Pharma announces seed investment

Updated: May 14

We have partnered with CanNegev Incubator that was established as a joint venture of Perrigo/Padagis, BOL Pharma, OurCrowd, and Israeli Innovation Authority, and received seed funding from the Israeli Innovation Authority to initiate our research.


We have partnered with CanNegev Incubator that was established as a joint venture of Perrigo/Padagis, BOL Pharma, OurCrowd, and Israeli Innovation Authority, and received seed funding from the Israeli Innovation Authority to initiate our research.


We have partnered with CanNegev Incubator that was established as a joint venture of Perrigo/Padagis, BOL Pharma, OurCrowd, and Israeli Innovation Authority, and received seed funding from the Israeli Innovation Authority to initiate our research.


We have partnered with CanNegev Incubator that was established as a joint venture of Perrigo/Padagis, BOL Pharma, OurCrowd, and Israeli Innovation Authority, and received seed funding from the Israeli Innovation Authority to initiate our research.

 
 
 

Comments


footer-logo-white.png

Led by a team of industry experts, 3R Pharma LTD is developing high-end and complex cannabinoids based therapies to address chronic ocular diseases for patients around the world.

Company

Contact

36 Hasaifan St, Ein Vered, Israel 4069600

Phone: +972-544-742750

© 2025 3R Pharma. All rights reserved

bottom of page